Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
Open Access
- 2 August 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 9 (9) , 599-609
Abstract
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I–III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy. For stage I disease, staging is most accurate. Primary treatment consists of surgery or stereotactic ablative radiotherapy. When a patient has stage II disease, staging is less accurate because more diagnostic modalities are necessary to stage the mediastinal lymph nodes. Surgery remains the primary treatment modality and platinum-based adjuvant chemotherapy gives a 4% 5-year survival benefit. Staging patients with stage III disease is difficult because of the heterogeneity of the patients. It should be decided if a patient has potentially resectable disease with or without risk of incomplete resection. Induction therapy with chemo(radio)therapy followed by surgical resection or definitive chemoradiotherapy are the treatments of choice. The 5-year survival can reach 44% in selected patients. Decisions in staging and treating patients with NSCLC should be made by a multidisciplinary team with sufficient expertise in all aspects of staging and treatment.Keywords
This publication has 50 references indexed in Scilit:
- Nationwide Quality Improvement in Lung Cancer Care: The Role of the Danish Lung Cancer Group and RegistryJournal of Thoracic Oncology, 2013
- Negative Predictive Value of Positron Emission Tomography and Computed Tomography for Stage T1-2N0 Non–Small-Cell Lung Cancer: A Meta-AnalysisClinical Lung Cancer, 2012
- False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2012
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Quality study of a lung cancer committee: study of agreement between preoperative and pathological stagingEuropean Journal of Cardio-Thoracic Surgery, 2010
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Problems in the current diagnostic standards of clinical N1 non-small cell lung cancerThorax, 2007
- Video-Assisted Mediastinoscopic Surgery: Clinical Feasibility and Accuracy of Mediastinal Lymph Node StagingThe Annals of Thoracic Surgery, 2006
- Comparison Between Clinical and Pathologic Staging in 2,994 Cases of Lung CancerThe Annals of Thoracic Surgery, 2005
- Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinomaEuropean Journal of Cardio-Thoracic Surgery, 1997